Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The current study examines an adapted guided self-help stress reduction program, focusing on reducing stress in the time of COVID-19. Two studies are planned: 1) an international study in English in which individuals proficient in English throughout the world will participate and 2) a follow-up study in Hebrew.
Description: change in a self-report measure of stress during the COVID-19 pandemic that ranges from 0-128. Higher means more symptomatic.
Measure: The CoRonavIruS Health Impact Survey (CRISIS) Time: change from Pre to post treatment (6 weeks),Description: change in a self-report measure of stress during the COVID-19 pandemic that ranges from 0-128. Higher means more symptomatic.
Measure: The CoRonavIruS Health Impact Survey (CRISIS) Time: change from Pre to 6 months Follow-upDescription: change in a self-report measure of stress during the COVID-19 pandemic that ranges from 0-128. Higher means more symptomatic.
Measure: The CoRonavIruS Health Impact Survey (CRISIS) Time: change from Pre to 1 year Follow-upDescription: a self-report measure of depression, anxiety and stress, with each subscale ranging from 0-28. Higher means more symptomatic.
Measure: Depression, Anxiety, and Stress Scale- 21 item version: DASS-21 Time: Weekly change during treatment and at pre and post (6 week) treatment evaluationsDescription: a self-report measure of depression, anxiety and stress, with each subscale ranging from 0-28. Higher means more symptomatic.
Measure: Depression, Anxiety, and Stress Scale- 21 item version: DASS-21 Time: change from pre to 6 month follow upDescription: a self-report measure of depression, anxiety and stress, with each subscale ranging from 0-28. Higher means more symptomatic.
Measure: Depression, Anxiety, and Stress Scale- 21 item version: DASS-21 Time: change from pre to 1 year follow-upDescription: how many modules each individual completes, with less than 2 being considered dropout
Measure: completion rate of modules Time: 6 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports